
    
      Phase III open Study, multicenter, prospective, randomized entrance of a total of 188
      patients, 94 patients will receive medication test and 94 patients will receive OtosynalarÂ®.

      Patients will be assessed until the clinical condition has been resolved or a maximum of 3
      days.

      188 patients of either gender or race, who have at least two of the following symptoms: pain,
      discharge, tinnitus, ear fullness, subjective hearing loss temporary dizziness or vertigo.
      And with a clinical or non-acute external otitis.
    
  